CoChat

The Clinical and Economic Burden of Newly Diagnosed Alzheimer’s Disease in a Medicare Advantage Population

Open access
Suehs, Brandon T., Davis, Cralen D., Alvir, Jose, van Amerongen, Derek, PharmD, Nick C. Patel, Joshi, Ashish V., Faison, Warachal E., Shah, Sonali N. · 2013 · American Journal of Alzheimer's Disease & Other Dementias®

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Abstract

Background/Rationale: Alzheimer’s disease (AD) represents a serious public health issue affecting approximately 5.4 million individuals in the United States and is projected to affect up to 16 million by 2050. This study examined health care resource utilization (HCRU), costs, and comorbidity burden immediately preceding new diagnosis of AD and 2 years after diagnosis. Methods: This study utilized a claims-based, retrospective cohort design. Medicare Advantage members newly diagnosed with AD (n = 3374) were compared to matched non-AD controls (n = 6748). All patients with AD were required to have 12 months of continuous enrollment prior to AD diagnosis (International Classification of Diseases, Clinical Modification [ICD-9] 331.0), during which time no diagnosis of AD, a related dementia, or an AD medication was observed. Non-AD controls demonstrated no diagnosis of AD, a related dementia, or a prescription claim for an AD medication treatment during their health plan enrollment. Medical and pharmacy claims data were used to measure HCRU, costs, and comorbidity burden over a period of 36 months (12 months pre-diagnosis and 24 months post-diagnosis). Results: The HCRU and costs were greater for AD members during the year prior to diagnosis and during postdiagnosis years 1 and 2 compared to controls. The AD members also displayed greater comorbidity than their non-AD counterparts during postdiagnosis years 1 and 2, as measured by 2 different comorbidity indices. Conclusions: Members newly diagnosed with AD demonstrated greater HCRU, health care costs, and comorbidity burden compared to matched non-AD controls.

Overview

Integrity signals

Registry

Crossref · 10.1177/1533317513488911

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 38 references

Research works printed but not linked: 4

  1. Menzin J, 1999, Am J Geriatr Psychiatry, 7, 300
  2. Linkins K, 2000, Drug Benefit Trends, 12, 6
  3. Fillit H, 2002, Fam Med, 34, 528
  4. Farley JF, 2006, Am J Manag Care, 12, 110

Cited by

See all 71

Metadata

Authors
Suehs, B. T., Davis, C. D., Alvir, J., van Amerongen, D., PharmD, N. C. P., Joshi, A. V., Faison, W. E., & Shah, S. N.
Affiliations
  • Competitive Health Analytics, Inc, Louisville, KY, USA
  • Pfizer (United States) (US)
  • Humana, Inc, Cincinnati, OH, USA
Corresponding author
Suehs, Brandon T.
Venue
American Journal of Alzheimer's Disease & Other Dementias®
Published
2013-05-17
Volume
28
Issue
4
Pages
384-392
ISSN
  • 0888-4897 (ISSN-L)
  • 1533-3175
  • 1938-2731
OpenAlex
W2314796676
Cited by
71
References
38
Citations by year
2026: 1 · 2025: 3 · 2024: 2 · 2023: 7 · 2022: 8 · 2021: 6 · 2020: 7 · 2019: 6 · 2018: 7 · 2017: 6 · 2016: 4 · 2015: 7 · 2014: 7
FWCI
4.27
Type
journal article
Language
en
Open access
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • American Journal of Alzheimer s Disease & Other Dementias® (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
Pfizer
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
Alzheimer's disease, Medicare Advantage, healthcare resource utilization, health care costs, comorbidity burden, comorbidity index, dementia, economic burden, clinical burden
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Health Expenditures, Female, Health Services, Humans, Insurance Claim Review, Longitudinal Studies, Male, Retrospective Studies, United States, Comorbidity, Health Care Costs, Cost of Illness, Medicare Part C

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Clinical and Economic Burden of Newly Diagnosed Alzheimer’s Disease in a Medicare Advantage Population. https://app.cochat.ai/papers/10.1177/1533317513488911
The paper
Suehs, B. T., Davis, C. D., Alvir, J., van Amerongen, D., PharmD, N. C. P., Joshi, A. V., Faison, W. E., & Shah, S. N. (2013). The Clinical and Economic Burden of Newly Diagnosed Alzheimer’s Disease in a Medicare Advantage Population. American Journal of Alzheimer's Disease & Other Dementias®. https://doi.org/10.1177/1533317513488911

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.